All subcategories » published RCT
Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutation.
primary studies published RCT
Details- 2021
- Berkers G
Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection.
primary studies published RCT
Details- 2021
- Bilton D
Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis.
primary studies published RCT
Details- 2021
- Derichs N
The clinical and microbiological utility of inhaled aztreonam lysine for the treatment of acute pulmonary exacerbations of cystic fibrosis: An open-label randomised crossover study (AZTEC-CF).
primary studies published RCT
Details- 2021
- Frost F
Comparison of biosimilar Tigerase and Pulmozyme in long-term symptomatic therapy of patients with cystic fibrosis and severe pulmonary impairment (subgroup analysis of a Phase III randomized open-label clinical trial (NCT04468100)).
primary studies published RCT
Details- 2021
- Amelina EL
VO(2max) as an exercise tolerance endpoint in people with cystic fibrosis: Lessons from a lumacaftor/ivacaftor trial.
primary studies published RCT
Details- 2021
- Wilson J
A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation.
primary studies published RCT
Details- 2021
- Davies JC
Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT.
primary studies published RCT
Details- 2021
- Langton Hewer SC
Manuka honey versus saline sinus irrigation in the treatment of cystic fibrosis-associated chronic rhinosinusitis: A randomised pilot trial.
primary studies published RCT
Details- 2021
- Lee VS
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
primary studies published RCT
Details- 2021
- Sutharsan S